Darolutamide is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.
|NCPE Assessment Process||Complete|
|Rapid Review commissioned||27/04/2020|
|Rapid Review completed||25/05/2020|
|Rapid Review Outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of darolutamide compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||27/05/2020|
|Current status||Pre-submission consultation scheduled|